Drug Trial Radar · NCT05944926
Improving Outcomes in Depression in Primary Care in a Low Resource Setting
Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,500
Planned (sponsor's estimate)
Start
Mar 18, 2024
Primary completion
Apr 10, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Harvard Medical School (HMS and HSDM)Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Sangath; All India Institute of Medical Sciences, Bhopal; Vanderbilt University; Brigham and Women's Hospital; Centre for Addiction and Mental Health; Massachusetts General Hospital; Harvard School of Public Health (HSPH); National Institute of Mental Health (NIMH)
- First posted
- Jul 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Health services research
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The OptimizeD study aims to improve outcomes in depression in primary care in India. This study will randomize 1500 patients with moderate to severe depression to either psychotherapy based on behavioral activation called the Healthy Activity Program (HAP) or antidepressant medication (fluoxetine). The study has two primary objectives: 1. Use patient characteristics to generate a precision treatment rule based on baseline information for predicting in advance what works best for whom (and which patients are unlikely to respond to either treatment and should be referred to specialist care). 2. Conduct a cost-effectiveness analysis by comparing relative costs and effectiveness between those who were randomly allocated to their optimal treatment with those who were randomly allocated to a non-optimal treatment based on the precision treatment rule.
Conditions
- Depression
- Depressive Disorder
Interventions
Healthy Activity Program (HAP)Behavioral
HAP, delivered over 6-8 sessions by non-specialist healthcare workers, has behavioural activation as the core psychological strategy along with other strategies such as problem-solving and activation of social networks.
Antidepressant medication (fluoxetine)Drug
Patients assigned to antidepressant medication will start on fluoxetine 20 mg/day and can be raised to 40 mg/day (the maximum mandated by treatment guidelines for primary care in India) at week 3 or 6 for patients who have yet to remit. Participants who do not tolerate fluoxetine can be switched to escitalopram at week 6 (10mg which can be titrated up to 20 mg).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Depression remissionTime frame: 3 months post recruitment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sangath
Bhopal, Madhya Pradesh, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.